

Julio Pascual

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3922920/publications.pdf>

Version: 2024-02-01

126
papers

5,969
citations

87888

38
h-index

74163

75
g-index

152
all docs

152
docs citations

152
times ranked

3142
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of Chronic Daily Headache in the General Population. <i>Headache</i> , 1999, 39, 190-196.	3.9	627
2	Ergotamine in the acute treatment of migraine: A review and European consensus. <i>Brain</i> , 2000, 123, 9-18.	7.6	329
3	Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. <i>Neurology</i> , 2013, 81, 1191-1196.	1.1	327
4	Guidelines for Controlled Trials of Prophylactic Treatment of Chronic Migraine in Adults. <i>Cephalalgia</i> , 2008, 28, 484-495.	3.9	270
5	Chronic daily headache with analgesic overuse. <i>Neurology</i> , 2004, 62, 1338-1342.	1.1	248
6	Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). <i>Journal of Headache and Pain</i> , 2012, 13, 361-378.	6.0	248
7	Cough, exertional, and sexual headaches. <i>Neurology</i> , 1996, 46, 1520-1524.	1.1	229
8	Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases. <i>Brain</i> , 1997, 120, 1105-1113.	7.6	159
9	Correlation Between Lipophilicity and Triptan Outcomes. <i>Headache</i> , 2005, 45, 3-6.	3.9	147
10	Quality of life in chronic daily headache. <i>Neurology</i> , 2002, 58, 1062-1065.	1.1	144
11	Premonitory and Resolution Symptoms in Migraine: A Prospective Study in 100 Unselected Patients. <i>Cephalalgia</i> , 2006, 26, 1051-1060.	3.9	144
12	OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. <i>Pain</i> , 2015, 156, 820-824.	4.2	136
13	<sc>CGRP</sc> and <sc>VIP</sc> Levels as Predictors of Efficacy of Onabotulinumtoxin Type <sc>A</sc> in Chronic Migraine. <i>Headache</i> , 2014, 54, 987-995.	3.9	132
14	Epidemiology of chronic daily headache. <i>Current Pain and Headache Reports</i> , 2001, 5, 529-536.	2.9	128
15	Headache in type I Chiari malformation. <i>Neurology</i> , 1992, 42, 1519-1519.	1.1	122
16	Withinâ€Patient Early Versus Delayed Treatment of Migraine Attacks With Almotriptan: The Sooner the Better. <i>Headache</i> , 2002, 42, 28-31.	3.9	108
17	Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. <i>Synapse</i> , 1997, 26, 341-350.	1.2	98
18	Headaches precipitated by cough, prolonged exercise or sexual activity: a prospective etiological and clinical study. <i>Journal of Headache and Pain</i> , 2008, 9, 259-266.	6.0	98

#	ARTICLE	IF	CITATIONS
19	European headache federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , 2015, 17, 5.	6.0	97
20	Consistent Efficacy and Tolerability of Almotriptan in the Acute Treatment of Multiple Migraine Attacks: Results of a Large, Randomized, Double-Blind, Placebo-Controlled Study. <i>Cephalalgia</i> , 2000, 20, 588-596.	3.9	92
21	Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?. <i>Cephalalgia</i> , 2015, 35, 864-868.	3.9	89
22	Preventing Disturbing Migraine Aura With Lamotrigine: An Open Study. <i>Headache</i> , 2004, 44, 1024-1028.	3.9	87
23	Comparison of Rizatriptan 10 Mg vs. Zolmitriptan 2.5 Mg in the Acute Treatment of Migraine. <i>Cephalalgia</i> , 2000, 20, 455-461.	3.9	74
24	Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. <i>Cephalalgia</i> , 2015, 35, 310-316.	3.9	68
25	Tolerability and Efficacy of Almotriptan in the Long-Term Treatment of Migraine. <i>European Neurology</i> , 2001, 45, 206-213.	1.4	56
26	Combined Therapy for Migraine Prevention? Clinical Experience with A β -Blocker Plus Sodium Valproate in 52 Resistant Migraine Patients. <i>Cephalalgia</i> , 2003, 23, 961-962.	3.9	53
27	Testing the combination beta-blocker plus topiramate in refractory migraine. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 81-83.	2.1	53
28	Prevalence of cranial autonomic parasympathetic symptoms in chronic migraine: Usefulness of a new scale. <i>Cephalalgia</i> , 2016, 36, 346-350.	3.9	53
29	Neuropeptides as a Marker for Chronic Headache. <i>Current Pain and Headache Reports</i> , 2017, 21, 18.	2.9	53
30	Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. <i>Current Opinion in Neurology</i> , 2017, 30, 281-286.	3.6	50
31	Autoradiographic Distribution of [3H]sumatriptan-Binding Sites in Post-Mortem Human Brain. <i>Cephalalgia</i> , 1996, 16, 317-322.	3.9	49
32	Orgasmic Headaches: Clinical Features, Diagnosis, and Management. <i>Headache</i> , 2000, 40, 491-494.	3.9	49
33	How Does Almotriptan Compare With Other Triptans? A Review of Data From Placebo-Controlled Clinical Trials. <i>Headache</i> , 2002, 42, 99-113.	3.9	49
34	Comparison of Preference for Rizatriptan 10-mg Wafer versus Sumatriptan 50-mg Tablet in Migraine. <i>European Neurology</i> , 2001, 45, 275-283.	1.4	46
35	Smoking as a precipitating factor for migraine: a survey in medical students. <i>Journal of Headache and Pain</i> , 2009, 10, 101-103.	6.0	46
36	Cerebral Blood Flow Changes in Pseudomigraine with Pleocytosis Analyzed by Single Photon Emission Computed Tomography. A Spreading Depression Mechanism?. <i>Cephalalgia</i> , 1998, 18, 570-573.	3.9	44

#	ARTICLE	IF	CITATIONS
37	125I-Galanin Binding Sites in Alzheimer's Disease: Increases in Hippocampal Subfields and a Decrease in the Caudate Nucleus. <i>Journal of Neurochemistry</i> , 2002, 68, 1106-1113.	3.9	43
38	Spinocerebellar ataxia type 2 with levodopa-responsive parkinsonism culminating in motor neuron disease. <i>Movement Disorders</i> , 2004, 19, 848-852.	3.9	42
39	Clinical Benefits of Early Triptan Therapy for Migraine. <i>Headache</i> , 2002, 42, 10-17.	3.9	41
40	Effect of Rizatriptan and Other Triptans on the Nausea Symptom of Migraine: A Post Hoc Analysis. <i>Headache</i> , 2001, 41, 754-763.	3.9	38
41	Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe. <i>Cephalgia</i> , 2017, 37, 1384-1397.	3.9	38
42	Pseudomigraine with lymphocytic pleocytosis. <i>Current Pain and Headache Reports</i> , 2003, 7, 224-228.	2.9	36
43	Almotriptan and zolmitriptan in the acute treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 2007, 115, 34-40.	2.1	34
44	Long-Term Evolution of Chronic Daily Headache With Medication Overuse in the General Population. <i>Headache</i> , 2010, 50, 981-988.	3.9	33
45	Experience with onabotulinumtoxinA (BOTOX) in chronic refractory migraine: focus on severe attacks. <i>Journal of Headache and Pain</i> , 2011, 12, 235-238.	6.0	33
46	Antiepileptic Drugs for the Treatment of Chronic and Episodic Cluster Headache: A Review.. <i>Headache</i> , 2007, 47, 81-9.	3.9	31
47	Transformed Migraine: A Proposal for the Modification of Its Diagnostic Criteria Based on Recent Epidemiological Data. <i>Cephalgia</i> , 1999, 19, 847-850.	3.9	30
48	Efficacy, Speed of Action and Tolerability of Almotriptan in the Acute Treatment of Migraine. <i>Cephalgia</i> , 2006, 26, 400-408.	3.9	28
49	An Open Preference Study with Sumatriptan 50 mg and Zolmitriptan 2.5 mg in 100 Migraine Patients. <i>Cephalgia</i> , 2001, 21, 680-684.	3.9	27
50	Primary cough headache. <i>Current Pain and Headache Reports</i> , 2005, 9, 272-276.	2.9	27
51	Experience with Intravenous Levetiracetam in Status Epilepticus. <i>CNS Drugs</i> , 2009, 23, 983-987.	5.9	27
52	Other Primary Headaches. <i>Neurologic Clinics</i> , 2009, 27, 557-571.	1.8	26
53	No Change in Interictal PACAP Levels in Peripheral Blood in Women With Chronic Migraine. <i>Headache</i> , 2016, 56, 1448-1454.	3.9	26
54	Is Chiari type I malformation a reason for chronic daily headache?. <i>Current Pain and Headache Reports</i> , 2007, 11, 53-55.	2.9	25

#	ARTICLE	IF	CITATIONS
55	Relationship between serum levels of VIP, but not of CGRP, and cranial autonomic parasympathetic symptoms: A study in chronic migraine patients. <i>Cephalalgia</i> , 2017, 37, 823-827.	3.9	25
56	Cardiac Cephalgia is Not Necessarily an Exertional Headache: Case Report. <i>Cephalalgia</i> , 2002, 22, 765-766.	3.9	24
57	What Differences Exist in the Appropriate Treatment of Congenital Versus Acquired Adult Chiari Type I Malformation?. <i>Current Pain and Headache Reports</i> , 2011, 15, 157-163.	2.9	21
58	How many migraine patients need prolonged (> 1 year) preventive treatment? Experience with topiramate. <i>Journal of Headache and Pain</i> , 2007, 8, 90-93.	6.0	20
59	Guillain-Barré syndrome after rituximab in a patient with idiopathic thrombocytopenic purpura: a causal association?. <i>Journal of Neurology</i> , 2010, 257, 488-489.	3.6	19
60	Comparison of Triptan Tablet Consumption per Attack: A Prospective Study of Migraineurs in Spain. <i>Headache</i> , 2002, 42, 93-98.	3.9	18
61	CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA. <i>Journal of Headache and Pain</i> , 2019, 20, 39.	6.0	18
62	How does the brain change in chronic migraine? Developing disease biomarkers. <i>Cephalalgia</i> , 2021, 41, 613-630.	3.9	18
63	IgG-mediated allergy: A new mechanism for migraine attacks?. <i>Cephalalgia</i> , 2010, 30, 777-779.	3.9	17
64	Necesidades de formación del médico de atención primaria en cefaleas. <i>Neurología</i> , 2010, 25, 104-107.	0.7	15
65	A review of rizatriptan, a quick and consistent 5-HT _{1B/1D} agonist for the acute treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 669-677.	1.8	14
66	CGRP en migraña: de la fisiopatología a la terapéutica. <i>Neurología</i> , 2022, 37, 390-402.	0.7	14
67	Efficacy of BMS-927711 and other gepants vs triptans: There seem to be other players besides CGRP. <i>Cephalalgia</i> , 2014, 34, 1028-1029.	3.9	13
68	Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example. <i>Journal of Headache and Pain</i> , 2006, 7, 27-33.	6.0	12
69	Evidencia y experiencia del uso de onabotulinumtoxinA en neuralgia del trigémino y cefaleas primarias distintas de la migraña crónica. <i>Neurología</i> , 2020, 35, 568-578.	0.7	12
70	CGRP antibodies: the Holy Grail for migraine prevention?. <i>Lancet Neurology</i> , The, 2015, 14, 1066-1067.	10.2	11
71	AMG 334 CGRP antibody for migraine: time to celebrate?. <i>Lancet Neurology</i> , The, 2016, 15, 347-349.	10.2	11
72	Evidencia y experiencia de b ³ tox en migraña crónica: Recomendaciones para la práctica clínica diaria. <i>Neurología</i> , 2019, 34, 408-417.	0.7	11

#	ARTICLE	IF	CITATIONS
73	Almotriptan: a review of 10 yearsâ€™ clinical experience. Expert Review of Neurotherapeutics, 2010, 10, 1505-1517.	2.8	10
74	Chronic migraine does not increase posterior circulation territory (PCT) infarct-like lesions. Journal of the Neurological Sciences, 2014, 336, 180-183.	0.6	10
75	Other Primary Headaches. Neurologic Clinics, 2019, 37, 871-891.	1.8	10
76	The Potential Role of the Glymphatic System in Headache Disorders. Pain Medicine, 2021, 22, 3098-3100.	1.9	10
77	Primary cough headache, primary exertional headache, and primary headache associated with sexual activity. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2010, 97, 459-468.	1.8	9
78	Bending the Rule of Monotherapy for Migraine Prevention?. Headache, 2005, 45, 748-750.	3.9	8
79	Autoradiographic studies of neurotransmitter receptors in the brain of newborn infants with Down syndrome. American Journal of Medical Genetics Part A, 2005, 37, 301-305.	2.4	8
80	Prevalence of primary headaches: it is not the behavior, but still we have to pay attention to it!. Journal of Headache and Pain, 2011, 12, 139-140.	6.0	8
81	Combination therapy for chronic migraine. Neurology, 2012, 78, 940-941.	1.1	8
82	No association between migraine frequency, white matter lesions and silent brain infarctions: a study in a series of women with chronic migraine. European Journal of Neurology, 2020, 27, 1689-1696.	3.3	8
83	Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings. Journal of Neural Transmission Supplementum, 1994, 42, 247-260.	0.5	8
84	Further studies on the biochemical characterization and autoradiographic distribution of [H]hemicholinium-3 binding sites in rat brain: a presynaptic cholinergic marker. Pharmacological Research, 1991, 24, 345-355.	7.1	7
85	Efficacy and Tolerability of Almotriptan in Postmarketing Surveillance Studies. European Neurology, 2005, 53, 34-40.	1.4	7
86	Treatment of hemicrania continua by occipital nerve stimulation with a bion device. Current Pain and Headache Reports, 2009, 13, 3-4.	2.9	7
87	Quality assurance in specialized headache units in Spain: an observational prospective study. Journal of Headache and Pain, 2019, 20, 73.	6.0	7
88	Peripheral, Interictal Serum S100B Levels are Not Increased in Chronic Migraine Patients. Headache, 2020, 60, 1705-1711.	3.9	7
89	A woman with daily headaches. Journal of Headache and Pain, 2005, 6, 91-92.	6.0	6
90	Topiramate for patients with refractory migraine: an observational, multicenter study in Spain. NeurologÃa, 2003, 18, 364-7.	0.7	6

#	ARTICLE	IF	CITATIONS
91	Documento de revisión y actualización de la cefalea por uso excesivo de medicación (CUEM). <i>Neurología</i> , 2021, 36, 229-240.	0.7	5
92	Restless legs-like syndrome as an emergent adverse event of CGRP monoclonal antibodies: A report of two cases. <i>Cephalalgia</i> , 2021, 41, 1272-1275.	3.9	5
93	First case of hemicrania continua responsive to galcanezumab. <i>Neurological Sciences</i> , 2021, 42, 4775-4776.	1.9	5
94	Use of almotriptan in triptan-experienced and triptan-naïve patients. <i>Current Medical Research and Opinion</i> , 2007, 23, 2433-2440.	1.9	4
95	Almotriptan in Triptan-Naïve Patients: New Evidence of Benefits. <i>Cephalalgia</i> , 2008, 28, 14-20.	3.9	4
96	Proposal of a clinical care pathway for quality and safe management of headache patients: a consensus study report. <i>BMJ Open</i> , 2020, 10, e037190.	1.9	4
97	Teaching needs of general practitioners in headaches. <i>Neurología (English Edition)</i> , 2010, 25, 104-107.	0.4	3
98	Is conventional brain MRI useful for the diagnosis of cluster headache in patients who meet ICHD-3 criteria? Experience in three hospitals in Spain. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120122.	0.6	3
99	Changes in acute headache medication use and health care resource utilization: Results from a randomized, double-blind, placebo-controlled clinical trial evaluating galcanezumab in adults with treatment-resistant migraine (CONQUER). <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-12.	0.9	3
100	Almotriptan: a novel 5-HT _{1B/D} agonist for the symptomatic treatment of migraine. <i>Expert Review of Neurotherapeutics</i> , 2001, 1, 20-27.	2.8	2
101	More lessons for the treatment of chronic daily headache. <i>Journal of Headache and Pain</i> , 2008, 9, 3-4.	6.0	2
102	Diferencias entre migraña crónica con y sin uso excesivo de medicación. <i>Neurología</i> , 2017, 32, 341-342.	0.7	2
103	Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice. <i>Neurología (English Edition)</i> , 2019, 34, 408-417.	0.4	2
104	Isolated De Novo Headache as the Presenting Symptom of Listeria Meningitis: A Report of 2 Cases. <i>Headache</i> , 2020, 60, 2573-2577.	3.9	2
105	I Reunión Post-European Headache Federation: revisión de las novedades presentadas en el Congreso de la European Headache Federation de 2020. <i>Revista De Neurología</i> , 2021, 72, S1.	7.8	2
106	El sistema glifático y su implicación en las enfermedades del sistema nervioso. <i>Medicina Clínica</i> , 2021, 156, 339-343.	0.6	2
107	Increase in Serum Calcitonin Gene-Related Peptide ¹ 2 (CGRP ¹ 2) Levels in COVID-19 Patients with Diarrhea: An Underlying Mechanism?. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5712-5713.	2.3	2
108	Migraine as a potential risk factor for ischemic lesions: Recent findings. <i>Current Pain and Headache Reports</i> , 2009, 13, 333-334.	2.9	1

#	ARTICLE	IF	CITATIONS
109	Almotriptan: a review of 20 yearsâ€™ clinical experience. Expert Review of Neurotherapeutics, 2019, 19, 759-768.	2.8	1
110	Cefalea y migraña. Medicine, 2019, 12, 4145-4153.	0.0	1
111	Tratamiento de la migraña en el año 2020. Medicina Clínica, 2019, 152, 226-228.	0.6	1
112	Chronic Migraine With Apparent Loss of Response to Onabotulinum Toxin Type A Due to Local Nitroglycerin Treatment for an Anal Fissure: A Case Report. Headache, 2020, 60, 2570-2572.	3.9	1
113	Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. Neurología (English) Tj ETQq1 1 0.784314 rgBT / Dv	0.4	1
114	Chiari headaches. Neurology, 1993, 43, 1272.	1.1	1
115	Treatment of chronic daily headache. Journal of Headache and Pain, 2004, 5, s92-s95.	6.0	0
116	Pharmacotherapy for Other Primary Headache Disorders. Headache, 2016, , 121-130.	0.4	0
117	Treatment of migraine in the year 2020. Medicina Clínica (English Edition), 2019, 152, 226-228.	0.2	0
118	Circulating CGRP levels in medication-overuse headache. Acta Neurologica Scandinavica, 2020, 141, 355-356.	2.1	0
119	The glymphatic system and its involvement in disorders of the nervous system. Medicina Clínica (English Edition), 2021, 156, 339-343.	0.2	0
120	Late vascular complications after cranial radiotherapy: A report of two illustrative cases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2021, 25, 786-789.	1.4	0
121	La cefalea como motivo principal de consulta a un servicio de urgencia hospitalaria en España: un estudio prospectivo. Neurología, 2023, 38, S31-S36.	0.7	0
122	Recent advances in the pharmacological management of migraine. F1000 Medicine Reports, 2009, 1, .	2.9	0
123	Cough and Exertional Headache, Primary. , 2014, , 881-884.		0
124	Syndrome of Transient Headache and Neurological Deficits with Cerebrospinal Fluid Lymphocytosis (HaNDL). Headache, 2015, , 59-64.	0.4	0
125	Response to Comment on "œels conventional brain MRI useful for the diagnosis of cluste headache in patients who meet ICHD-3 criteria? Experience in three hospitals in Spain". Journal of the Neurological Sciences, 2022, , 120176.	0.6	0
126	Increase in CGRP levels in a case of hemicrania continua normalizes after a successful response to galcanezumab. Neurological Sciences, 2022, , 1.	1.9	0